Physician profile
Ashutosh Chandel
NPI 1871594572
$5,778.28
in general payments reported to CMS, 2019-2025
18 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $794 · 2021: $1,087 · 2022: $841 · 2023: $883 · 2024: $555 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.97 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,080.14 | 2021-2025 | Cobalt Dr Mri Surescan, Reveal Linq, Azure Xt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $898.92 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $768.21 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $665.19 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $556.41 | 2019-2023 | |
| Medtronic Vascular, INC. | $502.19 | 2019-2020 | |
| Amgen INC. | $319.34 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.53 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $180.03 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $139.75 | 2019-2021 | |
| Boston Scientific Corporation | $118.70 | 2023 | Resonate El Icd Vr, Watchman Flx |
| Esperion Therapeutics, INC. | $106.35 | 2020-2022 | |
| Abbott Laboratories | $79.10 | 2022 | |
| Amarin Pharma, INC. | $77.32 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.53 | 2023-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.05 | 2020 | |
| Daiichi Sankyo INC. | $17.20 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Chandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.